MF equity cash holdings up by ₹4,000 cr amid volatile market

by Hansraj Agrawal | Mar 21, 2026 | Share Market

The MF ecosystem is heavily supported by consistent SIP inflows, which continue to remain strong even during volatile phases
| Photo Credit:
juststock

Mutual fund houses have increased the cash holding of equity schemes by ₹4,000 crore to ₹2.10 lakh crore in February against ₹2.06 lakh crore logged in January due to huge market volatility, according to JM Financial report.

However, the steady Systematic Investment Plan inflows and recent fall in markets opening up fresh buying avenues have kept the cash holdings under check. Part of the cash build-up can also be due to 8 equity schemes raising ₹3,955 crore through NFO last month. In January, 4 equity NFOs mopped up ₹806 crore.

SIPs hold fort

The inflows through SIP in last 11 months of this fiscal was up 10 per cent at ₹317,502 crore against ₹289,352 crore logged in the whole of FY’25.

Akshat Garg, Head – Research & Product at Choice Wealth said that less than 5 per cent cash holding of MFs does not necessarily mean that there are no redemption pressure but it is simply under the manageable limits.

“If there was real stress in the system, cash levels would have moved up sharply as fund managers prepared for outflows. That is clearly not happening right now,” he added.

The MF ecosystem is heavily supported by consistent SIP inflows, which continue to remain strong even during volatile phases and the steady inflows act as a natural counterbalance to redemptions, allowing fund managers to manage liquidity without holding excessive cash, said Garg.

In fact, in a falling market, holding higher cash can actually become a drag if markets rebound quickly and that is exactly why most funds prefer to remain close to fully invested, he said.

Market crash scares

The gross redemption from equity schemes has reduced to ₹36,098 crore in February against ₹41,639 crore in January. However, a consistent sharp fall in equity markets may scare new MF investors leading to higher redemptions and lower inflows.

Gibin John, Senior Investment Strategist, Geojit Investments said MFs continue to receive a strong and steady SIP inflows of around ₹29,000 to ₹30,000 crore per month, providing consistent liquidity support and reduces the need for holding higher cash.

Despite the huge volatility and recent meltdown in markets, the overall equity asset under management has increased 16 per cent to ₹35.39 lakh crore in February against ₹30.57 lakh crore in April, 2025.

However, the numbers in March will be crucial as the Sensex has already fallen 7 per cent so far this month to 74,533 points on Friday from 80,239 points on March 2. Signs of ending West Asia war will dictate the markets and fate of MF industry going ahead.

Published on March 21, 2026

Source link

Dr Reddy's launches Obeda (semaglutide) in India for Type 2 Diabetes

by Hansraj Agrawal | Mar 21, 2026 | Share Market

Dr Reddy’s Laboratories has announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to GLP-1 receptor agonist-based therapy for the management of Type 2 diabetes in India.

The company said it is the first Indian pharmaceutical firm to receive approval from the Drugs Controller General of India (DCGI) for generic semaglutide, enabling a day-one launch upon patent expiry. It added that the move reflects its readiness to serve unmet patient needs in India.

India faces one of the worlds largest diabetes burdens, with over 101 million adults living with the condition, according to the ICMR INDIAB study. The study estimates diabetes prevalence at 11.4%, with nearly four in ten adults experiencing abdominal obesity. An additional 136 million individuals are estimated to be pre diabetic, placing them at high risk of developing the disease. In such a scenario, semaglutide, a GLP-1 receptor agonist, has a globally proven track record in improving glycaemic control and supporting weight management when used as part of a comprehensive treatment plan.

The company stated a Phase III clinical study enrolling 312 participants, Dr. Reddys Obeda established non-inferior efficacy and a safety profile comparable to the innovator drug. It showed similar glycaemic reduction. Additionally, comparable results were observed for fasting glucose control, post-prandial glucose control, and therapeutic glycaemic response (achieving HbA1c <7.0%) at the end of the study. No anti-drug antibodies were detected, and the immunogenicity profile was similar to that of the innovator drug.

With both API development and manufacturing, as well as formulation development conducted entirely in house, Obeda reflects Dr. Reddys strength in complex product development and peptide science. It also showcases the companys decade long expertise in peptide technology and its commitment to bringing GLP 1 therapies to market to ensure access to high quality, affordable medicines and addressing Indias evolving healthcare needs. As part of its future plans for GLP-1 therapies, the company will be looking at a fully integrated API and formulation approach, encompassing both development and manufacturing in-house.

Obeda is available in 2 mg and 4 mg strengths as a once-weekly pre-filled pen for subcutaneous administration. The company said each pen delivers a minimum of four weekly doses, with a monthly treatment cost of ₹4,200.

Dr. Reddys also introduced a patient support programme called SemaKare, which includes digital onboarding support, injection training, tele-assistance, and adherence monitoring to improve patient outcomes.

As part of its broader strategy, the company said it plans to establish metabolic centres of excellence across India to improve diabetes care, enhance healthcare professional training, strengthen diagnostic capabilities, and drive patient awareness. It also noted collaboration with Dr. ReddysNestlHealth Science joint venture products to support nutritional needs of patients on GLP-1 therapies.

Erez Israeli, chief executive officer of Dr. Reddys, said: Todays launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complex product development and peptide science. It reinforces our vision to be a trusted partner in healthcare by combining innovation with access, ensuring advanced diabetes treatments are not only available but affordable. As part of phase-1 launch, we aim to introduce generic semaglutide in several countries and, through our One Product, One Quality approach, we are committed to ensure the same high quality product across all markets.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddys, said: As the first generic semaglutide approved in the country, todays announcement reflects our science led approach and our long standing efforts in expanding access to advanced therapies in India. With the country facing a rapidly rising diabetes burden, we aim to offer effective treatment options and enable more patients to benefit from globally established therapies. The launch of this important drug strengthens our diabetes portfolio and reinforces our broader commitment to improving long term health outcomes for people living with chronic metabolic diseases. GLP 1 therapies represent an important area of focus for us, and we will continue working toward building a full breadth portfolio for multiple metabolic indications across all formats.

Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company reported a 14.4% decline in consolidated net profit to Rs 1209.8 crore despite of 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The counter rose 1.95% to settle at Rs 1,298.95 on the BSE.

Powered by Capital Market – Live News

Source link

Mutual Funds returns

by Hansraj Agrawal | Mar 21, 2026 | Share Market

EQUITY – LARGE & MID CAP FUNDS

Bandhan Large & Mid Cap Fund

127.3

14780

1.7

0.5

5.6

22.0

17.7

15.9

0.58

HYBRID – AGGRESSIVE HYBRID FUNDS

BOI AXA Mid & Small Cap Eq&Debt

36.5

1360

2.0

0.7

5.7

18.2

16.5

–

0.48

HYBRID – BALANCED ADVANTAGE FUNDS

Baroda BNP Paribas Balanced Advantage Fund

23.6

4767

1.9

0.8

5.1

13.0

10.2

–

0.45

EQUITY – LARGE CAP FUNDS

Canara Robeco Large Cap Fund

57.6

17104

1.7

0.5

-1.4

13.1

10.4

13.6

0.37

EQUITY – TAX SAVING (ELSS) FUNDS

DSP ELSS Tax Saver Fund

129.4

17250

1.6

0.7

0.4

17.8

14.9

15.6

0.52

HYBRID – EQUITY SAVINGS FUNDS

Edelweiss Equity Savings Fund

25.6

1270

1.6

0.6

6.4

11.0

8.8

9.0

0.71

EQUITY – MID CAP FUNDS

Edelweiss Mid Cap Fund

95.1

14355

1.7

0.5

7.4

23.9

19.5

18.3

0.58

HYBRID – BALANCED ADVANTAGE FUNDS

HDFC Balanced Advantage Fund

498.1

107590

1.4

0.8

2.8

15.9

15.8

15.1

0.78

EQUITY – FLEXI CAP FUNDS

HDFC Flexi Cap Fund

1878.9

100455

1.3

0.7

3.4

19.4

18.4

16.5

0.71

EQUITY – FOCUSED FUNDS

HDFC Focused Fund

216.0

27136

1.6

0.6

2.4

18.6

19.4

15.0

0.78

EQUITY – LARGE & MID CAP FUNDS

HDFC Large and Mid Cap Fund

311.1

28580

1.6

0.9

1.8

18.0

16.3

14.6

0.55

EQUITY – MID CAP FUNDS

HDFC Mid Cap Fund

185.3

94257

1.4

0.8

8.2

23.5

20.6

18.1

0.70

EQUITY – VALUE FUNDS

HSBC Value Fund

105.1

14750

1.7

0.7

8.5

21.0

18.4

16.3

0.58

EQUITY – DIVIDEND YIELD FUNDS

ICICI Prudential Dividend Yield Equity Fund

50.2

6531

1.8

0.6

4.3

20.3

20.1

16.2

0.80

HYBRID – AGGRESSIVE HYBRID FUNDS

ICICI Prudential Equity & Debt Fund

384.7

50205

1.5

0.9

5.8

17.7

17.6

15.8

0.85

EQUITY – FOCUSED FUNDS

ICICI Prudential Focused Equity Fund

86.2

15145

1.7

0.6

5.1

20.2

16.8

15.1

0.59

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

ICICI Prudential Infrastructure Fund

180.9

8098

1.9

1.2

3.6

21.7

24.3

17.9

0.85

EQUITY – LARGE & MID CAP FUNDS

ICICI Prudential Large & Mid Cap Fund

950.8

28506

1.6

0.8

4.1

19.2

18.2

15.7

0.69

EQUITY – LARGE CAP FUNDS

ICICI Prudential Large Cap Fund

103.1

77452

1.4

0.9

1.7

15.8

13.8

14.3

0.52

EQUITY – SECTOR – PHARMA FUNDS

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

37.2

6801

1.9

1.0

2.5

27.0

17.4

–

0.59

HYBRID – CONSERVATIVE HYBRID FUNDS

ICICI Prudential Regular Savings Fund

76.5

3341

1.7

1.0

5.7

9.7

8.4

9.4

0.91

EQUITY – VALUE FUNDS

ICICI Prudential Value Fund

450.3

60571

1.5

1.0

4.1

18.6

18.5

15.5

0.80

EQUITY – FLEXI CAP FUNDS

JM Flexicap Fund

86.9

5159

1.8

0.7

-4.2

17.7

15.4

16.3

0.49

HYBRID – CONSERVATIVE HYBRID FUNDS

Kotak Debt Hybrid Fund

58.1

3031

1.7

0.5

3.3

9.4

8.6

9.2

0.74

EQUITY – THEMATIC – CONSUMPTION FUNDS

Nippon India Consumption Fund

171.3

2512

2.0

0.6

-5.4

12.1

13.9

12.9

0.46

EQUITY – LARGE CAP FUNDS

Nippon India Large Cap Fund

84.5

51404

1.5

0.7

2.6

16.9

15.7

14.6

0.56

EQUITY – SMALL CAP FUNDS

Nippon India Small Cap Fund

151.9

67642

1.4

0.7

1.8

19.2

21.1

20.5

0.57

EQUITY – FLEXI CAP FUNDS

Parag Parikh Flexi Cap Fund

80.2

134253

1.3

0.6

2.3

17.8

15.9

17.2

0.66

HYBRID – AGGRESSIVE HYBRID FUNDS

Quant Aggressive Hybrid Fund

403.2

1990

2.1

0.8

5.3

12.3

14.3

15.1

0.53

EQUITY – TAX SAVING (ELSS) FUNDS

Quant ELSS Tax Saver Fund

346.7

12080

1.7

0.8

5.5

15.9

17.3

19.6

0.48

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Quant Infrastructure Fund

33.5

2869

2.0

0.8

-2.8

16.0

20.0

18.4

0.52

EQUITY – MID CAP FUNDS

Quant Mid Cap Fund

191.1

7341

1.8

0.8

-5.7

15.2

17.7

15.8

0.50

EQUITY – SMALL CAP FUNDS

Quant Small Cap Fund

227.6

27654

1.6

0.8

-0.9

18.7

22.5

17.6

0.55

EQUITY – TAX SAVING (ELSS) FUNDS

SBI ELSS Tax Saver Fund

406.3

32171

1.6

0.9

0.3

20.7

17.5

14.7

0.63

EQUITY – SECTOR – IT FUNDS

SBI Technology Opportunities Fund

182.5

4273

1.9

0.9

-7.5

9.7

11.4

14.7

0.31

HYBRID – EQUITY SAVINGS FUNDS

Sundaram Equity Savings Fund

68.6

1182

2.2

0.7

2.3

10.6

9.4

9.2

0.58

EQUITY – SECTOR – BANKING FUNDS

Sundaram Financial Services Opportunities Fund

98.8

1684

2.1

0.8

6.1

16.9

13.0

15.1

0.39

EQUITY – FOCUSED FUNDS

360 ONE Focused Fund

42.7

6837

1.8

0.8

-2.7

13.0

12.3

15.6

0.40

HYBRID – BALANCED ADVANTAGE FUNDS

Aditya Birla SL Bal Advantage

104.2

9104

1.8

0.7

5.2

12.1

9.8

10.9

0.55

EQUITY – LARGE & MID CAP FUNDS

Axis Large & Mid Cap Fund

30.5

15559

1.7

0.6

3.3

18.3

13.7

–

0.42

EQUITY – SMALL CAP FUNDS

AXIS Small Cap Fund

95.6

26008

1.6

0.6

0.7

16.1

17.4

17.8

0.54

EQUITY – TAX SAVING (ELSS) FUNDS

Bandhan ELSS Tax Saver Fund

143.0

7056

1.8

0.7

2.1

13.9

15.0

0.46

EQUITY – VALUE FUNDS

Bandhan Value Fund

137.3

10145

1.8

0.7

0.3

15.1

16.5

15.8

0.55

EQUITY – TAX SAVING (ELSS) FUNDS

Bank of India ELSS Tax Saver

151.2

1384

2.0

0.8

2.5

16.7

14.1

16.0

0.39

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

BOI AXA Manufacturing & Infra

56.3

689

2.2

0.6

12.9

23.8

20.9

18.0

0.59

EQUITY – SMALL CAP FUNDS

Bank of India Small Cap Fund

41.6

1904

2.0

0.5

0.2

18.2

18.1

–

0.45

HYBRID – AGGRESSIVE HYBRID FUNDS

Baroda BNP Paribas Aggressive Hybrid Fund

26.4

1250

2.1

0.5

2.2

13.2

10.8

–

0.41

EQUITY – THEMATIC – CONSUMPTION FUNDS

Baroda BNP Paribas India Consumption Fund

27.9

1455

2.1

0.6

-5.1

12.9

11.5

–

0.35

EQUITY – THEMATIC – CONSUMPTION FUNDS

Canara Robeco Consumer Trends Fund

96.3

1950

2.1

0.8

-3.4

13.1

11.6

15.4

0.37

EQUITY – TAX SAVING (ELSS) FUNDS

Canara Robeco ELSS Tax Saver

163.5

8800

1.7

0.6

2.4

13.9

11.6

14.6

0.39

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Canara Robeco Infrastructure Fund

156.6

934

2.3

1.0

9.7

24.6

22.5

16.6

0.67

EQUITY – SECTOR – PHARMA FUNDS

DSP Healthcare Fund

36.4

3033

1.9

0.7

-2.9

20.9

14.4

–

0.46

HYBRID – AGGRESSIVE HYBRID FUNDS

Edelweiss Aggressive Hybrid Fund

60.3

3546

1.9

0.4

2.3

15.1

13.5

12.4

0.59

HYBRID – BALANCED ADVANTAGE FUNDS

Edelweiss Balanced Advantage Fund

49.6

13176

1.7

0.5

3.6

11.5

9.6

10.7

0.44

EQUITY – FLEXI CAP FUNDS

Edelweiss Flexi Cap Fund

35.8

3203

1.9

0.4

3.3

17.0

13.9

14.7

0.44

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Franklin Build India Fund

136.5

3174

2.0

1.0

7.5

25.1

22.1

17.8

0.68

EQUITY – DIVIDEND YIELD FUNDS

Franklin India Dividend Yield Fund

130.7

2409

2.1

1.2

-0.3

14.4

15.7

15.2

0.70

EQUITY – FLEXI CAP FUNDS

Franklin India Flexi Cap Fund

1495.8

19598

1.7

0.9

-0.6

16.1

14.2

13.5

0.47

EQUITY – FOCUSED FUNDS

Franklin India Focused Equity Fund

97.4

12129

1.8

1.0

-1.2

13.8

13.1

13.8

0.42

EQUITY – TAX SAVING (ELSS) FUNDS

HDFC ELSS Tax saver

1295.8

16618

1.7

1.1

0.7

18.1

17.3

14.2

0.68

HYBRID – EQUITY SAVINGS FUNDS

HDFC Equity Savings Fund

65.8

5901

1.9

0.9

4.8

9.6

9.0

9.7

0.63

HYBRID – CONSERVATIVE HYBRID FUNDS

HDFC Hybrid Debt Fund

82.1

3340

1.8

1.2

3.5

9.3

8.9

0.84

EQUITY – LARGE CAP FUNDS

HDFC Large Cap Fund

1057.5

40085

1.6

1.0

-0.5

13.5

12.7

13.4

0.46

HYBRID – BALANCED ADVANTAGE FUNDS

ICICI Prudential Balanced Advantage Fund

73.3

71151

1.4

0.9

6.5

12.2

10.6

11.2

0.72

EQUITY – SECTOR – IT FUNDS

ICICI Prudential Technology Fund

165.1

13572

1.8

1.0

-11.6

8.1

8.8

15.0

0.24

EQUITY – SECTOR – BANKING FUNDS

Invesco India Financial Services Fund

132.1

1650

2.1

0.8

9.5

19.9

14.0

15.7

0.40

EQUITY – MID CAP FUNDS

Invesco India Midcap Fund

163.5

10772

1.7

0.5

8.6

24.7

18.9

17.8

0.54

EQUITY – SMALL CAP FUNDS

Invesco India Smallcap Fund

37.9

9716

1.7

0.4

4.9

22.3

19.8

–

0.53

HYBRID – AGGRESSIVE HYBRID FUNDS

JM Aggressive Hybrid Fund

108.7

735

2.3

0.9

-4.0

15.5

13.3

11.7

0.48

EQUITY – TAX SAVING (ELSS) FUNDS

JM ELSS Tax Saver Fund

43.5

217

2.4

1.0

-2.0

16.4

13.6

15.3

0.41

EQUITY – LARGE CAP FUNDS

JM Large Cap Fund

142.4

443

2.4

0.9

0.7

13.6

11.4

10.9

0.38

HYBRID – AGGRESSIVE HYBRID FUNDS

Kotak Aggressive Hybrid Fund

59.4

8653

1.7

0.5

5.2

13.6

12.1

12.8

0.50

HYBRID – EQUITY SAVINGS FUNDS

Kotak Equity Savings Fund

26.3

9853

1.7

0.7

6.5

10.6

9.4

9.2

0.71

EQUITY – LARGE CAP FUNDS

Kotak Large Cap Fund

533.2

10925

1.7

0.6

1.8

13.5

11.2

12.7

0.40

EQUITY – MID CAP FUNDS

Mahindra Manulife Mid Cap Fund

31.8

4440

1.9

0.6

5.8

23.0

19.2

–

0.56

EQUITY – TAX SAVING (ELSS) FUNDS

Mirae Asset ELSS Tax Saver Fund

45.5

26203

1.6

0.6

3.5

15.4

12.4

16.9

0.41

HYBRID – EQUITY SAVINGS FUNDS

Mirae Asset Equity Savings Fund

20.3

1901

1.4

0.4

6.3

11.1

9.1

–

0.59

EQUITY – MID CAP FUNDS

Motilal Oswal Midcap Fund

83.7

33689

1.6

0.8

-8.3

19.3

20.9

16.2

0.55

EQUITY – SECTOR – BANKING FUNDS

Nippon India Banking & Financial Services Fund

594.5

7869

1.8

1.0

6.3

16.8

14.9

14.5

0.44

EQUITY – MID CAP FUNDS

Nippon India Growth Mid Cap Fund

3971.2

43983

1.5

0.7

9.1

24.5

20.6

18.6

0.64

EQUITY – VALUE FUNDS

Nippon India Value Fund

209.5

9034

1.8

1.1

1.8

20.6

16.7

16.0

0.54

EQUITY – FLEXI CAP FUNDS

PGIM India Flexi Cap Fund

33.0

6004

1.8

0.5

0.1

11.0

10.4

13.5

0.32

EQUITY – LARGE & MID CAP FUNDS

Quant Large & Mid Cap Fund

102.5

3070

2.0

0.8

-4.1

14.7

14.8

15.3

0.43

HYBRID – CONSERVATIVE HYBRID FUNDS

SBI Conservative Hybrid Fund

73.4

9871

1.5

1.0

5.9

9.6

9.0

8.8

0.88

EQUITY – FOCUSED FUNDS

SBI Focused Fund

349.7

43311

1.5

0.7

9.2

17.3

13.4

14.7

0.48

EQUITY – LARGE & MID CAP FUNDS

SBI Large & Midcap Fund

598.6

38766

1.6

0.7

6.0

16.6

16.0

15.2

0.59

EQUITY – LARGE CAP FUNDS

SBI Large Cap Fund

86.6

55246

1.5

0.8

1.6

12.6

10.8

12.3

0.39

EQUITY – FLEXI CAP FUNDS

Union Flexi Cap Fund

46.8

2349

2.0

0.9

0.8

13.8

11.8

13.1

0.38

HYBRID – AGGRESSIVE HYBRID FUNDS

UTI Aggressive Hybrid Fund

387.7

6663

1.9

1.2

2.5

15.1

13.5

12.4

0.59

HYBRID – EQUITY SAVINGS FUNDS

UTI Equity Savings Fund

18.4

835

1.7

0.7

4.7

10.1

9.1

–

0.69

EQUITY – LARGE & MID CAP FUNDS

UTI Large & Mid Cap Fund

170.4

5724

1.8

0.9

4.5

20.5

16.6

14.3

0.58

EQUITY – SECTOR – BANKING FUNDS

Aditya Birla SL Bank & Fin Serv

57.4

3673

2.0

1.0

5.9

15.5

11.3

13.9

0.32

EQUITY – THEMATIC – CONSUMPTION FUNDS

Aditya Birla Sun Life Consumption Fund

190.4

6184

1.8

0.8

-2.4

12.4

11.6

14.1

0.37

EQUITY – FLEXI CAP FUNDS

Aditya Birla Sun Life Flexi Cap Fund

1711.3

25207

1.7

0.9

5.3

16.8

13.0

14.2

0.42

EQUITY – FOCUSED FUNDS

Aditya Birla Sun Life Focused Fund

134.3

7971

1.8

0.9

3.2

15.8

12.2

12.8

0.43

EQUITY – LARGE CAP FUNDS

Aditya Birla Sun Life Large Cap Fund

482.0

30094

1.6

1.0

-0.1

13.3

11.4

12.2

0.40

HYBRID – CONSERVATIVE HYBRID FUNDS

Aditya Birla Sun Life Regular Savings Fund

67.7

1523

1.8

0.9

6.0

8.9

8.0

8.6

0.74

HYBRID – BALANCED ADVANTAGE FUNDS

Axis Balanced Advantage Fund

20.5

3799

1.9

0.7

2.6

13.7

10.1

–

0.54

HYBRID – EQUITY SAVINGS FUNDS

Axis Equity Savings Fund

22.0

902

2.3

1.0

3.7

9.9

7.6

8.5

0.41

EQUITY – MID CAP FUNDS

Axis Midcap Fund

105.8

31977

1.6

0.6

5.6

18.6

14.3

16.7

0.44

HYBRID – AGGRESSIVE HYBRID FUNDS

Bandhan Aggressive Hybrid Fund

25.2

1747

2.1

0.6

6.3

15.1

12.4

–

0.46

EQUITY – FLEXI CAP FUNDS

Bandhan Flexi Cap Fund

193.8

7427

1.9

1.1

2.9

14.8

11.7

11.2

0.38

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Bandhan Infrastructure Fund

43.9

1469

2.1

0.9

-2.5

21.0

19.4

15.8

0.49

EQUITY – LARGE CAP FUNDS

Bandhan Large Cap Fund

72.1

2024

2.0

0.9

2.5

15.6

11.7

12.6

0.38

EQUITY – LARGE & MID CAP FUNDS

BOI Large & Mid Cap Equity Fund

84.3

456

2.3

1.1

6.2

16.3

14.2

12.9

0.44

EQUITY – TAX SAVING (ELSS) FUNDS

Baroda BNP Paribas ELSS Tax Saver Fund

90.2

906

2.2

1.0

3.7

17.8

12.1

12.7

0.37

EQUITY – LARGE CAP FUNDS

Baroda BNP Paribas Large Cap Fund

205.9

2639

2.0

0.8

1.1

14.3

11.7

12.8

0.40

EQUITY – MID CAP FUNDS

Baroda BNP Paribas Mid Cap Fund

98.1

2341

2.0

0.5

7.3

19.8

16.4

15.7

0.51

HYBRID – CONSERVATIVE HYBRID FUNDS

Canara Robeco Conservative Hybrid Fund

95.2

887

1.9

0.7

2.1

7.4

6.5

7.8

0.48

HYBRID – AGGRESSIVE HYBRID FUNDS

Canara Robeco Equity Hybrid Fund

342.7

11268

1.7

0.6

3.1

12.6

10.3

12.5

0.42

EQUITY – FLEXI CAP FUNDS

Canara Robeco Flexi Cap Fund

312.0

13390

1.7

0.6

1.3

13.7

11.3

14.1

0.39

EQUITY – LARGE & MID CAP FUNDS

Canara Robeco Large and Mid Cap Fund

227.9

24731

1.6

0.6

-3.0

14.3

12.0

15.3

0.38

HYBRID – AGGRESSIVE HYBRID FUNDS

DSP Aggressive Hybrid Fund

333.0

11928

1.7

0.7

-0.8

14.2

10.6

12.4

0.41

HYBRID – BALANCED ADVANTAGE FUNDS

DSP Dynamic Asset Allocation Fund

27.4

3732

1.9

0.6

4.5

12.1

8.2

9.0

0.47

HYBRID – EQUITY SAVINGS FUNDS

DSP Equity Savings Fund

21.8

3758

1.5

0.7

3.5

9.8

8.4

–

0.68

EQUITY – FLEXI CAP FUNDS

DSP Flexi Cap Fund

93.3

12165

1.7

0.7

-1.6

15.2

11.4

14.1

0.36

EQUITY – FOCUSED FUNDS

DSP Focused Fund

49.5

2607

2.0

1.0

-2.4

16.8

11.2

12.0

0.38

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

DSP India T.I.G.E.R. Fund

306.7

5460

1.9

0.7

9.3

24.4

23.1

17.4

0.66

EQUITY – LARGE & MID CAP FUNDS

DSP Large & Mid Cap Fund

577.6

17653

1.7

0.6

1.1

18.6

14.7

15.1

0.51

HYBRID – CONSERVATIVE HYBRID FUNDS

DSP Regular Savings Fund

59.0

184

1.2

0.5

3.8

9.5

7.7

7.2

0.66

EQUITY – SMALL CAP FUNDS

DSP Small Cap Fund

180.8

16886

1.7

0.8

6.2

18.5

18.2

16.3

0.49

EQUITY – LARGE & MID CAP FUNDS

Edelweiss Large & Mid Cap Fund

81.8

4485

1.8

0.4

4.1

17.3

13.9

14.6

0.45

EQUITY – LARGE CAP FUNDS

Edelweiss Large Cap Fund

78.3

1477

2.1

0.6

0.9

13.1

11.2

12.8

0.39

HYBRID – AGGRESSIVE HYBRID FUNDS

Franklin India Aggressive Hybrid Fund

253.2

2350

2.0

0.9

0.0

12.7

10.7

11.0

0.43

HYBRID – CONSERVATIVE HYBRID FUNDS

Franklin India Conservative Hybrid Fund

90.0

197

1.4

0.7

3.7

8.5

7.1

7.2

0.56

EQUITY – TAX SAVING (ELSS) FUNDS

Franklin India ELSS Tax Saver Fund

1335.3

6407

1.8

1.1

-1.8

15.7

13.7

12.7

0.45

EQUITY – LARGE CAP FUNDS

Franklin India Large Cap Fund

954.2

7580

1.9

1.1

1.8

13.2

9.8

11.0

0.32

EQUITY – SECTOR – IT FUNDS

Franklin India Technology Fund

434.7

1670

2.1

1.1

-8.7

14.9

9.5

14.3

0.24

HYBRID – AGGRESSIVE HYBRID FUNDS

HDFC Hybrid Equity Fund

109.4

23811

1.7

1.0

-0.5

9.4

10.2

11.5

0.43

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

HDFC Infrastructure Fund

43.4

2417

2.1

1.2

2.2

24.0

22.2

12.5

0.66

EQUITY – SMALL CAP FUNDS

HDFC Small Cap Fund

123.0

37424

1.6

0.7

3.7

16.1

18.8

17.5

0.53

EQUITY – VALUE FUNDS

HDFC Value Fund

694.9

7413

1.8

1.0

5.0

17.4

14.8

13.9

0.49

HYBRID – BALANCED ADVANTAGE FUNDS

HSBC Balanced Advantage Fund

41.8

1535

2.1

0.8

2.3

10.5

7.8

8.2

0.38

HYBRID – CONSERVATIVE HYBRID FUNDS

HSBC Conservative Hybrid Fund

60.8

139

2.1

1.1

4.4

9.3

7.4

7.5

0.43

HYBRID – EQUITY SAVINGS FUNDS

HSBC Equity Savings Fund

34.1

780

1.5

0.7

9.6

13.2

10.7

9.1

0.50

EQUITY – FLEXI CAP FUNDS

HSBC Flexi Cap Fund

199.7

5279

1.9

1.2

2.9

16.9

13.3

12.9

0.39

EQUITY – SECTOR – BANKING FUNDS

ICICI Prudential Banking & Financial Services Fund

122.6

10886

1.8

1.0

2.4

13.5

10.9

14.3

0.33

EQUITY – TAX SAVING (ELSS) FUNDS

ICICI Pru Long Term Equity

865.5

14353

1.7

1.1

1.8

15.0

12.3

13.1

0.43

EQUITY – MID CAP FUNDS

ICICI Prudential Midcap Fund

298.6

7280

1.9

1.0

16.6

23.9

18.7

16.6

0.59

EQUITY – SMALL CAP FUNDS

ICICI Prudential Smallcap Fund

77.2

8355

1.8

0.8

1.2

14.0

16.3

15.4

0.55

HYBRID – BALANCED ADVANTAGE FUNDS

Invesco India Balanced Advantage Fund

50.1

1066

2.1

0.8

-1.2

10.6

8.7

9.6

0.36

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Invesco India Infrastructure Fund

56.4

1370

2.2

0.9

1.4

20.8

19.9

16.6

0.54

EQUITY – LARGE & MID CAP FUNDS

Invesco India Large & Mid Cap Fund

90.3

9392

1.8

0.6

5.2

22.1

15.7

15.5

0.46

EQUITY – LARGE CAP FUNDS

Invesco India Largecap Fund

63.1

1702

2.0

0.7

1.3

15.2

12.2

12.4

0.39

EQUITY – VALUE FUNDS

JM Value Fund

83.6

858

2.3

1.2

-5.8

16.1

14.8

15.9

0.45

HYBRID – BALANCED ADVANTAGE FUNDS

Kotak Balanced Advantage Fund

19.8

17591

1.7

0.6

3.1

10.2

8.6

–

0.46

EQUITY – TAX SAVING (ELSS) FUNDS

Kotak ELSS Tax Saver Fund

106.2

6355

1.8

0.6

1.4

13.4

12.8

14.2

0.42

EQUITY – FLEXI CAP FUNDS

Kotak Flexicap Fund

79.4

56853

1.4

0.6

4.2

15.3

12.2

13.9

0.41

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Kotak Infra & Economic Reform

60.6

2339

2.0

0.7

7.0

17.2

19.6

15.4

0.56

EQUITY – LARGE & MID CAP FUNDS

Kotak Large & Midcap Fund

324.4

30712

1.6

0.6

5.5

17.6

15.1

15.6

0.51

EQUITY – MID CAP FUNDS

Kotak Midcap Fund

125.9

61694

1.4

0.4

8.1

19.4

17.4

17.8

0.55

EQUITY – SMALL CAP FUNDS

Kotak Small Cap Fund

225.5

16871

1.7

0.6

-3.1

12.9

13.9

16.2

0.40

EQUITY – DIVIDEND YIELD FUNDS

LIC MF Dividend Yield Fund

27.8

662

2.3

0.8

0.1

18.7

14.8

–

0.48

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

LIC MF Infrastructure Fund

47.0

1007

2.2

1.0

9.1

26.8

22.5

16.4

0.60

EQUITY – TAX SAVING (ELSS) FUNDS

Mahindra Manulife ELSS Tax Saver Fund

26.0

936

2.2

0.7

-0.5

12.4

11.8

–

0.39

HYBRID – EQUITY SAVINGS FUNDS

Mahi Manu Eq Sav Dhan San Yojana

20.6

553

2.4

0.8

5.6

9.9

8.3

–

0.45

HYBRID – AGGRESSIVE HYBRID FUNDS

Mirae Asset Aggressive Hybrid Fund

31.2

9530

1.7

0.4

5.2

13.2

10.7

12.5

0.43

EQUITY – THEMATIC – CONSUMPTION FUNDS

Mirae Asset Great Consumer Fund

81.8

4473

1.9

0.4

-2.2

13.3

13.1

15.1

0.39

EQUITY – SECTOR – PHARMA FUNDS

Mirae Asset Healthcare Fund

38.2

2844

1.9

0.5

5.3

24.8

16.1

–

0.51

EQUITY – LARGE & MID CAP FUNDS

Mirae Asset Large & Midcap Fund

141.5

42943

1.5

0.6

5.4

15.9

12.6

17.0

0.41

EQUITY – LARGE CAP FUNDS

Mirae Asset Large Cap Fund

103.7

40184

1.5

0.6

0.3

11.4

9.6

13.0

0.32

EQUITY – TAX SAVING (ELSS) FUNDS

Motilal Oswal ELSS Tax Saver Fund

47.7

4175

1.8

0.7

5.3

21.9

16.8

16.5

0.40

HYBRID – BALANCED ADVANTAGE FUNDS

Nippon India Balanced Advantage Fund

172.0

9688

1.7

0.6

3.6

11.5

9.5

11.0

0.53

EQUITY – FOCUSED FUNDS

Nippon India Focused Fund

112.3

8497

1.8

1.1

3.4

13.6

11.7

14.2

0.37

EQUITY – SECTOR – PHARMA FUNDS

Nippon India Pharma Fund

497.0

8306

1.8

0.9

2.6

23.1

15.6

14.1

0.51

EQUITY – LARGE & MID CAP FUNDS

Nippon India Vision Large & Mid Cap Fund

1362.5

6963

1.9

1.1

2.6

19.0

15.4

13.1

0.51

EQUITY – MID CAP FUNDS

PGIM India Midcap Fund

57.7

10877

1.7

0.5

-0.2

11.8

13.2

15.3

0.42

EQUITY – FOCUSED FUNDS

Quant Focused Fund

76.1

827

2.3

0.9

-2.6

12.5

11.3

13.2

0.37

EQUITY – TAX SAVING (ELSS) FUNDS

Quantum ELSS Tax Saver Fund

112.1

218

2.1

0.9

-3.5

14.2

11.5

11.6

0.44

EQUITY – SECTOR – BANKING FUNDS

SBI Banking & Financial Services Fund

41.4

10725

1.8

0.7

10.5

19.7

12.7

16.7

0.37

EQUITY – THEMATIC – CONSUMPTION FUNDS

SBI Consumption Opportunities Fund

268.3

2970

2.0

0.9

-8.3

10.5

14.0

13.9

0.44

HYBRID – AGGRESSIVE HYBRID FUNDS

SBI Equity Hybrid Fund

288.5

82318

1.4

0.7

4.2

13.8

10.9

12.0

0.48

HYBRID – EQUITY SAVINGS FUNDS

SBI Equity Savings Fund

24.0

5731

1.5

0.9

6.5

11.1

8.8

0.53

EQUITY – FLEXI CAP FUNDS

SBI Flexicap Fund

100.8

23297

1.7

0.8

0.6

11.4

10.0

12.3

0.34

EQUITY – SECTOR – PHARMA FUNDS

SBI Healthcare Opportunities Fund

417.4

4077

1.9

0.9

1.6

24.8

17.5

12.0

0.59

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

SBI Infrastructure Fund

45.3

4646

1.9

1.0

0.3

18.5

18.8

16.0

0.59

EQUITY – MID CAP FUNDS

SBI Midcap Fund

215.8

23154

1.7

0.9

-1.3

15.2

15.6

14.4

0.51

HYBRID – AGGRESSIVE HYBRID FUNDS

Sundaram Aggressive Hybrid Fund

151.0

8142

1.8

0.8

0.1

11.5

9.9

12.1

0.40

EQUITY – TAX SAVING (ELSS) FUNDS

Sundaram ELSS Tax Saver Fund

467.9

1349

2.2

1.5

0.8

13.7

12.3

13.8

0.42

EQUITY – FOCUSED FUNDS

Sundaram Focused Fund

146.5

1056

2.3

1.2

-1.1

12.5

10.5

13.2

0.32

EQUITY – MID CAP FUNDS

Sundaram Mid Cap Fund

1308.8

13235

1.7

0.9

7.6

23.0

17.9

15.2

0.55

EQUITY – SMALL CAP FUNDS

Sundaram Small Cap Fund

232.3

3306

1.9

0.8

4.7

17.3

14.2

0.47

HYBRID – AGGRESSIVE HYBRID FUNDS

Tata Aggressive Hybrid Fund

410.3

4024

1.9

1.0

0.2

9.9

9.6

9.9

0.38

EQUITY – SECTOR – BANKING FUNDS

Tata Banking and Financial Services Fund

40.7

3261

1.9

0.5

6.9

15.9

11.6

15.3

0.33

EQUITY – TAX SAVING (ELSS) FUNDS

Tata ELSS Fund

42.1

4674

1.8

0.7

3.9

15.1

12.6

14.0

0.41

EQUITY – FLEXI CAP FUNDS

Tata Flexi Cap Fund

22.4

3699

1.9

0.6

2.3

15.1

10.8

–

0.37

EQUITY – THEMATIC – CONSUMPTION FUNDS

Tata India Consumer Fund

39.8

2491

2.0

0.8

-1.7

15.3

13.1

15.5

0.38

EQUITY – LARGE CAP FUNDS

Tata Large Cap Fund

469.1

2784

2.0

1.0

0.8

13.2

11.4

11.9

0.39

EQUITY – MID CAP FUNDS

Tata Mid Cap Fund

412.0

5505

1.8

0.6

7.1

20.3

16.3

16.2

0.52

EQUITY – SMALL CAP FUNDS

Tata Small Cap Fund

31.5

10715

1.7

0.4

-12.6

11.2

16.2

–

0.45

EQUITY – VALUE FUNDS

Templeton India Value Fund

669.3

2257

2.0

0.9

2.3

15.3

15.9

14.4

0.56

HYBRID – BALANCED ADVANTAGE FUNDS

Union Balanced Advantage Fund

19.4

1305

2.2

1.0

1.7

8.6

6.8

–

0.32

EQUITY – TAX SAVING (ELSS) FUNDS

Union ELSS Tax Saver Fund

59.6

876

2.3

1.3

1.2

13.7

12.3

12.8

0.41

EQUITY – SMALL CAP FUNDS

Union Small Cap Fund

46.2

1787

2.1

1.0

8.2

18.2

17.1

15.5

0.44

EQUITY – VALUE FUNDS

Union Value Fund

26.5

375

2.5

1.2

3.8

16.9

14.0

–

0.48

HYBRID – CONSERVATIVE HYBRID FUNDS

UTI Conservative Hybrid Fund

68.7

1686

1.8

1.3

3.2

8.9

8.3

8.0

0.70

EQUITY – DIVIDEND YIELD FUNDS

UTI Dividend Yield Fund

167.8

3880

2.0

1.5

2.9

18.1

15.0

14.3

0.55

EQUITY – LARGE CAP FUNDS

UTI Large Cap Fund

248.5

12658

1.8

0.9

-1.8

10.8

9.1

11.6

0.30

EQUITY – VALUE FUNDS

UTI Value Fund

155.3

9787

1.8

1.2

0.5

16.7

13.4

13.7

0.47

EQUITY – SECTOR – IT FUNDS

Aditya Birla Sun Life Digital India Fund

138.5

3883

1.9

0.8

-12.5

6.1

7.6

14.6

0.20

EQUITY – DIVIDEND YIELD FUNDS

Aditya Birla Sun Life Dividend Yield Fund

426.6

1495

2.2

1.4

3.5

17.5

16.9

13.2

0.58

HYBRID – AGGRESSIVE HYBRID FUNDS

Aditya Birla Sun Life Equity Hybrid ’95 Fund

1431.6

7287

1.9

1.1

1.8

12.5

9.5

10.2

0.35

HYBRID – EQUITY SAVINGS FUNDS

Aditya Birla Sun Life Equity Savings Fund

22.5

1076

1.0

0.5

6.9

9.8

7.0

8.1

0.32

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Aditya Birla Sun Life Infrastructure Fund

89.8

1120

2.3

1.4

6.4

19.9

18.0

14.7

0.49

EQUITY – MID CAP FUNDS

Aditya Birla Sun Life Midcap Fund

723.8

6130

1.9

1.0

3.3

18.7

15.8

13.6

0.48

EQUITY – VALUE FUNDS

Aditya Birla Sun Life Value Fund

118.0

6259

1.9

1.0

3.4

19.0

14.9

12.3

0.41

HYBRID – CONSERVATIVE HYBRID FUNDS

Axis Conservative Hybrid Fund

30.0

232

2.2

1.2

3.4

7.2

6.1

6.7

0.36

EQUITY – FLEXI CAP FUNDS

Axis Flexi Cap Fund

24.3

12871

1.7

0.7

0.6

13.8

9.3

–

0.27

HYBRID – BALANCED ADVANTAGE FUNDS

Bandhan Balanced Advantage Fund

23.5

2231

2.0

0.8

2.6

10.4

7.6

8.4

0.31

EQUITY – FOCUSED FUNDS

Bandhan Focused Fund

80.3

2018

2.1

0.8

1.8

17.6

11.7

12.8

0.36

HYBRID – BALANCED ADVANTAGE FUNDS

Bank of India Balanced Advantage Fund

25.1

148

2.3

1.2

7.7

11.6

9.8

7.3

0.42

EQUITY – SECTOR – BANKING FUNDS

Baroda BNP Paribas Bank&Fin Serv

45.1

397

2.4

0.8

3.8

15.8

10.0

12.9

0.29

HYBRID – CONSERVATIVE HYBRID FUNDS

Baroda BNP Paribas Conser Hybrid

44.7

817

2.0

0.5

4.0

8.0

6.3

7.1

0.42

EQUITY – FOCUSED FUNDS

Baroda BNP Paribas Focused Fund

19.6

675

2.3

0.5

-1.0

11.7

10.0

–

0.28

EQUITY – LARGE CAP FUNDS

DSP Large Cap Fund

436.5

7270

1.8

0.9

-1.1

15.9

11.7

11.9

0.43

EQUITY – TAX SAVING (ELSS) FUNDS

Edelweiss Long Term Equity

104.5

439

2.3

0.7

4.6

15.2

12.1

12.2

0.38

HYBRID – EQUITY SAVINGS FUNDS

Franklin India Equity Savings Fund

16.6

675

1.1

0.4

4.6

8.4

7.4

–

0.45

EQUITY – LARGE & MID CAP FUNDS

Franklin India Large & Mid Cap Fund

173.7

3464

2.0

1.3

1.7

15.0

11.9

11.6

0.37

EQUITY – MID CAP FUNDS

Franklin India Mid Cap Fund

2483.8

12328

1.8

1.0

0.3

19.6

14.9

14.7

0.44

EQUITY – SMALL CAP FUNDS

Franklin India Small Cap Fund

150.5

12934

1.8

0.9

0.1

16.5

17.8

15.0

0.47

HYBRID – AGGRESSIVE HYBRID FUNDS

HSBC Aggressive Hybrid Fund

52.5

5459

1.9

0.8

7.1

13.9

10.4

10.8

0.32

EQUITY – TAX SAVING (ELSS) FUNDS

HSBC ELSS Tax saver Fund

124.0

4023

1.9

1.2

1.8

17.7

13.2

13.4

0.39

EQUITY – LARGE CAP FUNDS

HSBC Large Cap Fund

446.8

1894

2.1

1.3

2.7

13.7

10.4

12.5

0.33

EQUITY – SMALL CAP FUNDS

HSBC Small Cap Fund

69.7

15375

1.7

0.7

-3.4

14.5

18.4

17.6

0.47

HYBRID – EQUITY SAVINGS FUNDS

ICICI Prudential Equity Savings Fund

22.8

18027

1.0

0.5

4.8

8.0

7.5

8.2

1.00

HYBRID – AGGRESSIVE HYBRID FUNDS

Invesco India Aggressive Hybrid Fund

20.1

789

2.2

0.7

-4.4

13.0

9.8

–

0.34

EQUITY – TAX SAVING (ELSS) FUNDS

Invesco India ELSS Tax Saver Fund

108.1

2602

1.9

0.8

-4.7

13.8

9.9

12.6

0.28

EQUITY – FOCUSED FUNDS

JM Focused Fund

17.6

286

2.4

0.8

-5.5

14.6

12.0

13.2

0.34

EQUITY – LARGE & MID CAP FUNDS

LIC MF Large & Midcap Fund

35.3

3045

1.9

0.6

-0.7

16.5

13.0

14.6

0.42

EQUITY – LARGE CAP FUNDS

LIC MF Large Cap Fund

50.3

1422

2.2

1.1

-1.9

10.0

8.3

10.5

0.25

EQUITY – FLEXI CAP FUNDS

Motilal Oswal Flexi Cap Fund

52.5

12890

1.7

0.8

-6.6

19.3

10.6

12.5

0.30

HYBRID – AGGRESSIVE HYBRID FUNDS

Navi Aggressive Hybrid Fund

19.4

112

2.3

0.5

2.1

11.3

9.8

–

0.38

EQUITY – FLEXI CAP FUNDS

Navi Flexi Cap Fund

21.7

261

2.2

0.6

4.1

12.3

10.9

–

0.35

HYBRID – AGGRESSIVE HYBRID FUNDS

Nippon India Aggressive Hybrid Fund

100.0

4063

2.0

1.0

3.7

14.0

12.1

10.0

0.50

EQUITY – TAX SAVING (ELSS) FUNDS

Nippon India ELSS Tax Saver Fund

121.3

14959

1.7

1.0

4.7

16.9

14.3

11.4

0.47

EQUITY – TAX SAVING (ELSS) FUNDS

PGIM India ELSS Tax Saver Fund

30.7

726

2.3

0.8

-4.6

9.2

10.7

12.3

0.36

EQUITY – SMALL CAP FUNDS

SBI Small Cap Fund

151.8

34932

1.6

0.8

-2.3

12.2

14.2

17.4

0.42

HYBRID – BALANCED ADVANTAGE FUNDS

Sundaram Balanced Advantage Fund

33.4

1695

2.1

0.6

9.4

7.7

7.4

0.36

EQUITY – THEMATIC – CONSUMPTION FUNDS

Sundaram Consumption Fund

83.5

1458

2.2

1.2

-6.3

12.2

11.1

12.7

0.34

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Sundaram Infrastructure Advantage Fund

92.8

964

2.4

1.6

10.4

21.6

18.9

15.3

0.55

EQUITY – LARGE & MID CAP FUNDS

Sundaram Large and Mid Cap Fund

79.1

6868

1.8

0.7

2.0

15.2

12.6

14.0

0.40

EQUITY – SECTOR – PHARMA FUNDS

Tata India Pharma & Healthcare Fund

28.7

1301

2.1

0.7

0.5

22.7

15.2

11.7

0.50

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Tata Infrastructure Fund

156.5

2014

2.1

1.2

1.5

16.2

17.1

15.0

0.48

EQUITY – LARGE & MID CAP FUNDS

Tata Large & Mid Cap Fund

452.9

8143

1.8

0.7

-6.8

10.1

10.2

12.5

0.35

EQUITY – VALUE FUNDS

Tata Value Fund

329.1

8774

1.8

0.8

3.7

17.7

14.9

15.3

0.50

EQUITY – MID CAP FUNDS

Taurus Mid Cap Fund

107.7

123

2.5

1.9

1.0

14.2

12.5

14.9

0.35

HYBRID – EQUITY SAVINGS FUNDS

Union Equity Savings Fund

16.7

144

1.9

1.5

2.8

7.7

6.1

–

0.33

EQUITY – LARGE CAP FUNDS

Union Largecap Fund

21.7

453

2.5

1.7

-1.0

11.4

9.6

–

0.31

EQUITY – SECTOR – BANKING FUNDS

UTI Banking and Financial Services Fund

179.6

1425

2.1

1.1

4.9

15.2

11.3

12.2

0.33

EQUITY – TAX SAVING (ELSS) FUNDS

UTI ELSS Tax Saver Fund

186.5

3602

1.9

0.9

-1.0

12.0

9.6

11.9

0.29

EQUITY – FLEXI CAP FUNDS

UTI Flexi Cap Fund

275.9

22886

1.7

1.1

-7.3

8.4

5.5

11.3

0.14

EQUITY – THEMATIC – CONSUMPTION FUNDS

UTI India Consumer Fund

51.4

690

2.5

1.6

-1.6

12.2

10.1

10.9

0.30

EQUITY – MID CAP FUNDS

UTI Mid Cap Fund

275.2

11734

1.8

0.9

3.5

16.0

13.8

14.0

0.41

EQUITY – TAX SAVING (ELSS) FUNDS

Aditya Birla Sun Life ELSS Tax Saver Fund

56.1

14788

1.7

1.0

4.0

14.2

8.0

10.7

0.24

EQUITY – LARGE & MID CAP FUNDS

Aditya Birla Sun Life Large & Mid Cap Fund

841.5

5761

1.9

1.1

3.3

14.4

9.3

11.9

0.25

EQUITY – SMALL CAP FUNDS

Aditya Birla Sun Life Small Cap Fund

78.6

4882

1.9

0.9

5.5

17.0

13.2

12.9

0.34

HYBRID – AGGRESSIVE HYBRID FUNDS

Axis Aggressive Hybrid Fund

19.5

1505

2.2

1.1

1.6

11.2

8.3

–

0.28

EQUITY – TAX SAVING (ELSS) FUNDS

Axis ELSS Tax Saver Fund

87.8

33186

1.5

0.8

-1.8

13.7

7.5

11.9

0.19

EQUITY – FOCUSED FUNDS

Axis Focused Fund

48.7

11305

1.8

0.9

-3.4

10.8

5.2

11.5

0.11

EQUITY – LARGE CAP FUNDS

Axis Large Cap Fund

55.6

32437

1.6

0.7

-1.7

11.0

7.5

12.0

0.21

HYBRID – CONSERVATIVE HYBRID FUNDS

Bandhan Conservative Hybrid Fund

31.9

2.0

1.0

3.2

7.3

5.3

6.5

0.27

HYBRID – EQUITY SAVINGS FUNDS

Bandhan Equity Savings Fund

31.5

414

1.1

0.2

3.8

7.5

6.5

6.3

0.53

EQUITY – MID CAP FUNDS

DSP Midcap Fund

137.4

19641

1.7

0.7

6.9

19.1

12.8

15.0

0.38

EQUITY – LARGE CAP FUNDS

Groww Largecap Fund

40.0

132

2.5

1.3

2.9

12.6

9.9

11.3

0.31

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

HSBC Infrastructure Fund

44.0

2300

2.1

1.0

3.8

20.1

19.9

16.4

0.54

EQUITY – MID CAP FUNDS

HSBC Midcap Fund

375.5

12448

1.7

0.7

12.6

23.3

17.1

16.6

0.45

HYBRID – AGGRESSIVE HYBRID FUNDS

LIC MF Aggressive Hybrid Fund

182.7

518

2.5

1.4

1.5

11.7

8.6

9.3

0.31

EQUITY – SECTOR – BANKING FUNDS

LIC MF Banking & Financial Services Fund

20.0

277

2.5

1.2

7.9

11.3

9.7

9.9

0.27

EQUITY – TAX SAVING (ELSS) FUNDS

LIC MF ELSS Tax Saver

135.3

1045

2.2

1.0

-6.5

12.9

10.7

12.0

0.35

EQUITY – FLEXI CAP FUNDS

LIC MF Flexi Cap Fund

89.8

1000

2.3

1.6

3.6

12.8

9.7

9.9

0.29

EQUITY – MID CAP FUNDS

LIC MF Midcap Fund

26.1

337

2.5

1.4

-1.2

19.1

13.0

–

0.36

EQUITY – SMALL CAP FUNDS

LIC MF Small Cap Fund

26.9

606

2.4

1.0

-3.0

15.6

17.2

–

0.44

EQUITY – VALUE FUNDS

LIC MF Value Fund

23.4

203

2.5

1.4

7.2

15.2

12.5

–

0.34

EQUITY – THEMATIC – CONSUMPTION FUNDS

Mahindra Manulife Consumption Fund

19.9

513

2.4

0.8

-3.6

12.3

11.5

–

0.35

HYBRID – BALANCED ADVANTAGE FUNDS

Motilal Oswal Balanced Advantage Fund

17.1

769

2.3

1.1

-3.5

5.5

3.2

–

0.05

EQUITY – FOCUSED FUNDS

Motilal Oswal Focused Fund

40.7

1454

2.1

1.0

7.8

9.6

6.7

11.0

0.15

EQUITY – LARGE & MID CAP FUNDS

Navi Large & Midcap Fund

32.3

307

2.3

0.5

-0.1

11.4

11.2

12.8

0.35

HYBRID – CONSERVATIVE HYBRID FUNDS

Nippon India Conservative Hybrid Fund

60.0

948

1.9

1.1

8.0

8.9

8.1

5.8

1.13

HYBRID – EQUITY SAVINGS FUNDS

Nippon India Equity Savings Fund

16.1

929

1.6

0.5

4.4

8.5

7.1

4.9

0.46

HYBRID – AGGRESSIVE HYBRID FUNDS

PGIM India Aggressive Hybrid Equity Fund

119.6

207

2.3

0.8

-1.4

9.3

7.7

8.6

0.24

EQUITY – LARGE CAP FUNDS

PGIM India Large Cap Fund

309.0

568

2.4

0.8

-1.6

9.2

7.8

10.0

0.24

EQUITY – VALUE FUNDS

Quantum Value Fund

112.8

1151

2.1

1.1

-3.7

14.4

11.5

11.6

0.44

EQUITY – FLEXI CAP FUNDS

Shriram Flexi Cap Fund

18.3

131

2.4

0.5

-2.5

9.2

8.0

–

0.21

EQUITY – DIVIDEND YIELD FUNDS

Sundaram Dividend Yield Fund

128.0

894

2.3

1.1

1.6

14.7

12.9

15.0

0.47

EQUITY – SECTOR – IT FUNDS

Tata Digital India Fund

38.1

9896

1.7

0.5

-14.8

7.1

8.2

14.0

0.21

EQUITY – FLEXI CAP FUNDS

Taurus Flexi Cap Fund

205.3

346

2.7

2.6

-1.7

13.4

10.4

9.8

0.32

EQUITY – SECTOR – PHARMA FUNDS

UTI Healthcare Fund

274.3

1107

2.3

1.3

2.7

25.0

15.4

12.2

0.49

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

UTI Infrastructure Fund

131.8

2160

2.2

2.0

1.6

17.1

15.1

13.8

0.47

HYBRID – BALANCED ADVANTAGE FUNDS

UTI-Unit Linked Insurance Plan

39.9

5035

1.7

1.1

0.0

7.9

6.4

7.4

0.29

EQUITY – THEMATIC – MNC FUNDS

Aditya Birla Sun Life MNC Fund

–

1186.5

3437

2.0

1.3

-1.2

11.2

5.6

8.3

0.16

HYBRID – CONSERVATIVE HYBRID FUNDS

Bank of India Conservative Hybrid Fund

–

34.4

2.1

1.2

4.9

7.3

10.1

7.3

0.87

EQUITY – MULTI CAP FUNDS

Baroda BNP Paribas Multi Cap Fund

–

260.0

3096

2.0

0.9

-0.1

16.8

14.7

14.0

0.44

EQUITY – SMALL CAP FUNDS

Canara Robeco Small Cap Fund

–

34.3

12769

1.7

0.6

-0.4

13.8

17.5

–

0.52

EQUITY – SMALL CAP FUNDS

Edelweiss Small Cap Fund

–

39.4

5481

1.8

0.5

2.3

17.7

17.5

–

0.51

HYBRID – AGGRESSIVE HYBRID FUNDS

Groww Aggressive Hybrid Fund

–

19.5

2.5

1.5

1.0

10.1

8.6

–

0.31

EQUITY – TAX SAVING (ELSS) FUNDS

Groww ELSS Tax Saver Fund

–

17.8

2.4

0.9

-0.6

11.8

9.2

–

0.28

EQUITY – VALUE FUNDS

Groww Value Fund

–

24.7

2.5

1.1

3.0

15.3

11.8

10.3

0.40

EQUITY – LARGE & MID CAP FUNDS

HSBC Large & Mid Cap Fund

–

25.3

4706

1.9

0.8

8.2

19.0

14.4

–

0.37

EQUITY – THEMATIC – CONSUMPTION FUNDS

ICICI Prudential FMCG Fund

–

401.6

1765

2.2

1.4

-10.4

1.3

7.7

10.1

0.28

EQUITY – MULTI CAP FUNDS

ICICI Prudential Multicap Fund

–

741.8

16315

1.7

0.9

2.4

18.5

15.6

14.5

0.54

EQUITY – CONTRA FUNDS

Invesco India Contra Fund

–

120.5

19948

1.6

0.5

-1.4

17.2

13.8

15.3

0.45

HYBRID – EQUITY SAVINGS FUNDS

Invesco India Equity Savings Fund

–

16.0

354

2.3

0.8

-0.6

9.1

6.6

–

0.31

EQUITY – MULTI CAP FUNDS

Invesco India Multicap Fund

–

111.4

4001

1.9

0.7

-6.8

14.3

12.5

13.1

0.36

EQUITY – CONTRA FUNDS

Kotak Contra Fund

–

141.5

5225

1.8

0.6

4.9

18.5

15.2

16.0

0.53

HYBRID – CONSERVATIVE HYBRID FUNDS

LIC MF Conservative Hybrid Fund

–

82.2

2.3

1.4

3.6

6.4

5.4

6.4

0.31

HYBRID – EQUITY SAVINGS FUNDS

LIC MF Equity Savings Fund

–

27.0

2.4

1.3

4.0

8.8

6.8

6.5

0.30

EQUITY – FOCUSED FUNDS

LIC MF Focused Fund

–

19.4

164

2.4

0.5

0.8

9.7

9.4

–

0.28

EQUITY – SECTOR – PHARMA FUNDS

LIC MF Healthcare Fund

–

27.6

2.4

0.6

-1.5

21.2

12.0

–

0.36

EQUITY – LARGE CAP FUNDS

Mahindra Manulife Large Cap Fund

–

21.2

737

2.3

0.8

-0.4

12.8

10.3

–

0.34

EQUITY – MULTI CAP FUNDS

Mahindra Manulife Multi Cap Fund

–

33.2

6174

1.8

0.5

6.1

18.9

16.7

–

0.49

EQUITY – TAX SAVING (ELSS) FUNDS

Navi ELSS Tax Saver Fund

–

26.5

2.3

0.4

-0.3

10.8

9.1

10.7

0.27

EQUITY – MULTI CAP FUNDS

Nippon India Multi Cap Fund

–

275.9

50820

1.5

0.7

3.8

20.0

19.6

15.6

0.64

HYBRID – EQUITY SAVINGS FUNDS

PGIM India Equity Savings Fund

–

49.4

1.3

0.6

3.5

6.5

6.4

6.9

0.60

EQUITY – FLEXI CAP FUNDS

Quant Flexi Cap Fund

–

91.0

6354

1.8

0.7

1.5

16.1

18.0

18.7

0.52

EQUITY – MULTI CAP FUNDS

Quant Multi Cap Fund

–

554.4

7274

1.8

0.7

-4.2

11.2

13.2

16.6

0.36

EQUITY – CONTRA FUNDS

SBI Contra Fund

–

359.5

49111

1.5

0.7

1.7

17.1

18.7

16.0

0.75

EQUITY – THEMATIC – MNC FUNDS

SBI MNC Fund

–

338.5

5841

1.9

1.3

-0.3

6.7

8.5

10.5

0.27

HYBRID – AGGRESSIVE HYBRID FUNDS

Shriram Aggressive Hybrid Fund

–

30.0

2.4

0.9

2.6

10.4

8.2

9.3

0.28

EQUITY – TAX SAVING (ELSS) FUNDS

Shriram ELSS Tax Saver Fund

–

19.2

2.3

0.7

-1.8

9.6

7.9

–

0.21

HYBRID – CONSERVATIVE HYBRID FUNDS

Sundaram Conservative Hybrid Fund

–

29.1

1.1

0.8

1.3

6.3

6.8

6.5

0.54

EQUITY – MULTI CAP FUNDS

Sundaram Multi Cap Fund

–

344.7

2827

2.0

0.9

0.6

15.5

13.9

14.7

0.45

EQUITY – VALUE FUNDS

Sundaram Value Fund

–

202.5

1392

2.3

1.7

0.5

11.7

10.9

11.6

0.38

HYBRID – BALANCED ADVANTAGE FUNDS

Tata Balanced Advantage Fund

–

19.8

9604

1.7

0.5

2.0

9.6

8.7

–

0.49

EQUITY – SECTOR – BANKING FUNDS

Taurus Banking & Financial Services Fund

–

50.1

2.5

1.9

2.9

12.0

9.6

13.2

0.26

EQUITY – TAX SAVING (ELSS) FUNDS

Taurus ELSS Tax Saver Fund

–

166.2

2.5

1.7

-4.1

12.3

11.7

13.1

0.40

EQUITY – THEMATIC – INFRASTRUCTURE FUNDS

Taurus Infrastructure Fund

–

59.9

2.4

1.5

0.0

16.7

13.8

14.5

0.38

EQUITY – LARGE CAP FUNDS

Taurus Large Cap Fund

–

149.6

2.6

2.3

2.8

15.3

11.3

10.5

0.34

EQUITY – THEMATIC – MNC FUNDS

UTI MNC Fund

–

357.8

2724

2.1

1.3

1.5

11.1

9.4

9.8

0.33

Source link

Zydus Lifesciences launches semaglutide injection in India

by Hansraj Agrawal | Mar 21, 2026 | Share Market

Zydus Lifesciences has announced the launch of semaglutide injection in India under the brand names Semaglyntm, Mashematm, and Altermetm, following the expiry of the drug’s patent in the country.

The company said the Drug Controller General of India (DCGI) had earlier approved the manufacturing and marketing of the Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus Biotech Park in Ahmedabad. The company said the average monthly cost of therapy is expected to be around Rs 2,200.

Zydus also highlighted that diabetes and obesity are major public health challenges in India. Citing the International Diabetes Federation, it noted that 8.9 crore adults in India are living with diabetes, representing 10.5% of the adult population. The company further pointed out a sharp rise in obesity prevalence among adults, increasing by 91% in women and 146% in men, underscoring the growing burden of lifestyle-related diseases in the country.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The companys consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE.

Powered by Capital Market – Live News

Source link

Zydus launches semaglutide injection under three brands in India

by Hansraj Agrawal | Mar 21, 2026 | Share Market

Zydus Lifesciences has announced the launch of semaglutide injection in India under the brand names Semaglyntm, Mashematm, and Altermetm, following the expiry of the drug’s patent in the country.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The companys consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE.

Powered by Capital Market – Live News

Source link

Glenmark Pharma launches GLIPIQ (semaglutide) in India for Type 2 Diabetes at lower cost

by Hansraj Agrawal | Mar 21, 2026 | Share Market

Glenmark Pharmaceuticals has announced the launch of GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordable GLP-1 therapy aimed at expanding access to advanced diabetes treatment.

The company said the decision to start advanced injectable therapy is often delayed in many patients due to cost and complexity. With GLIPIQ, Glenmark aims to improve affordability and enable earlier treatment initiation across a broader patient population.

GLIPIQ has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India. The study demonstrated favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.

The drug is available in both vial and pre-filled pen formulations. The vial-based version, supported by dose-specific syringes, is designed to allow flexible, physician-guided dosing, particularly during the early stages of therapy. The company said this format is expected to offer a more cost-effective treatment option, with weekly therapy priced between Rs 325 and Rs 440.

The pre-filled pen formulation offers the convenience of self-dosing for long-term use. Together, the two formats are intended to provide a structured treatment pathway that supports adherence, continuity of care, and improved patient outcomes.

Alongside the product launch, Glenmark has introduced a patient support programme named Sankalp, aimed at assisting therapy initiation, improving comfort with injectable treatments, and supporting long-term adherence.

Semaglutide, a GLP-1 receptor agonist, is widely used in the management of Type 2 diabetes, particularly in patients with comorbidities such as obesity, cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease, due to its broader cardiometabolic benefits beyond glycaemic control.

Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals, said, Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs 325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.

Building on our experience in the GLP-1 category, including Lirafit (Liraglutide), and supported by our Sankalp program, we aim to help more patients access, initiate, and continue therapy over time.

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.

Shares of Glenmark Pharmaceuticals rallied 3.94% to Rs 2,181.05 on the BSE.

Powered by Capital Market – Live News

Source link

« Older Entries

Next Entries »

Times Top News

Times Top News

Recent Posts

Recent Comments